Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Dirk SchadendorfJason John LukePaolo Antonio AsciertoGeorgina V LongPiotr Lukasz RutkowskiAdnan KhattakMichele Del VecchioLuis de la Cruz MerinoJacek MackiewiczVanna Chiarion SileniJohn M KirkwoodCaroline RobertJean-Jacques GrobReinhard DummerMatteo S CarlinoYujie ZhaoMizuho KalabisClemens KreplerAlexander EggermontRichard A ScolyerPublished in: Journal for immunotherapy of cancer (2024)
ClinicalTrials.gov, NCT03553836.